Insulin detemir is more expensive than NPH insulin but is associated with higher quality-adjusted life-years because of the decreased incidence of hypoglycemia and incremental cost-effectiveness ratios.35,36 However, if cost is a major concern, NPH insulin is a reasonable therapy, since the absolute difference in hypoglycemia rates is small.